 |
 |
 |
 |
 |
I have two questions for the group to consider:-
1. I have just reviewed flow on a very interesting lymph node. We use =
CD45 vs SS gating on all diagnostic flow. The lymph node in question =
showed two distinct populations of cells in this strategy, one being an =
unremarkable population of lymphoid cells (30% of total) and the other =
population with precisely the same SS as lymphocytes but completely CD45 =
negative (3 decades lower than lymphocytes on the CD45 scale).
I assumed these to be non-haematologic cells (possibly carcinoma), on =
reviewing the histology of the node it looks like TB (ZN stain to =
follow) - so is the non-haematologic cell population the histocyte =
component of the disease process ??
The important question is ... what is the CD45 expression of histocytes, =
in particular do monocytes/macrophages loose their CD45 as they =
differentiate into the more epitheloid differentiation of histocytes ???
2. The second question arises from a recent response to the *clinical =
question*. One respondent suggested, among other things, the use of the =
CD45 v SS gating strategy. We use this strategy always; it's the =
backbone of all our clinical flow; and I'm always extolling colleagues =
to do the same - often without success because *it's too expensive* so =
how many other clinical labs use this routinely ???
Peter Chapple
Melbourne AUSTRALIA
|
|
|
|
|
|
CD-ROM Vol 3 was produced by Monica M. Shively and other staff at the
Purdue University Cytometry Laboratories and distributed free of charge
as an educational service to the cytometry community.
If you have any comments please direct them to
Dr. J. Paul Robinson, Professor & Director,
PUCL, Purdue University, West Lafayette, IN 47907.
Phone: (765)-494-0757;
FAX(765) 494-0517;
Web